E-mails Question FDA Review Process For Ketek

Law360, New York (July 19, 2006, 12:00 AM EDT) -- Several recently uncovered e-mails have exposed concern by Food and Drug Administration officials that the agency’s approval of a bronchitis treatment marketed by Sanofi-Aventis was a potentially lethal mistake.

An FDA official, David Graham, sent an e-mail last month questioning the approval of the drug, sold under the name Ketek, and claiming that the review process was fraught with error and oversight, the New York Times reported.

“It's as if every principle governing the review and approval of new drugs was abandoned or suspended where telithromycin...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.